Why BioMarin Pharmaceutical Is Back on Investor Radars

BioMarin Pharmaceutical (BMRN) has drawn fresh attention after recent share price swings, with the stock showing a small move over the past day, a gain over the past week, and declines over the month and past 3 months.

Looking beyond the latest move, BioMarin Pharmaceutical’s 90 day share price return of 6.15% sits against a weaker year to date share price return of 4.49% and a 1 year total shareholder return decline of 8.12%, which suggests recent momentum is rebuilding after a tougher stretch for long term holders.

If BioMarin’s moves have you reassessing the sector, this could be a good moment to scan other healthcare stocks that might fit your watchlist next.

With shares well below analyst targets and a sizeable intrinsic discount, yet recent returns still soft, you have to ask yourself: is BioMarin a misunderstood value in rare disease therapies, or is the market already pricing in future growth?

Most Popular Narrative: 36.7% Undervalued

With BioMarin Pharmaceutical last closing at $56.78 and the most followed narrative pointing to fair value at $89.74, the gap in expectations is hard to ignore.

Strong year over year revenue growth driven by increasing global demand, new patient starts, and international expansion of key therapies like VOXZOGO and VIMIZIM aligns with demographic shifts and improved rare disease diagnosis, supporting continued top line revenue growth.

Read the complete narrative. Read the complete narrative.

Want to see what is driving that higher fair value? The narrative focuses on compounding revenue, rising margins, and a richer future earnings multiple. The exact mix of those three levers may surprise you.

Result: Fair Value of $89.74 (UNDERVALUED)

However, this hinges on Voxzogo holding up against potential competitors and on BioMarin managing higher R&D and SG&A spending without squeezing future margins.

Build Your Own BioMarin Pharmaceutical Narrative

If this view does not quite match your own, or you would rather put the numbers to work yourself, you can build a fresh narrative in just a few minutes: Do it your way.

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding BioMarin Pharmaceutical.

Looking for more investment ideas?

If BioMarin has you thinking more broadly about opportunities, do not stop here. Widen your search and test fresh ideas before the next big move passes you by.

• Tap into potential growth stories at earlier stages by scanning these 3514 penny stocks with strong financials that still meet clear financial quality checks.
• Target companies using automation and data driven tools with these 23 AI penny stocks that connect real business models to AI themes.
• Look for possible pricing gaps by reviewing these 888 undervalued stocks based on cash flows that screen as relatively inexpensive on cash flow based metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.